molluscum contagiosum
Information
- Disease name
- molluscum contagiosum
- Disease ID
- DOID:8867
- Description
- "A viral infectious disease that results_in infection located_in skin, has_material_basis_in Molluscum contagiosum virus, which is transmitted_by contact with the skin, and transmitted_by fomites. The infection has_symptom lesions which are flesh-colored with a pit in the center." [url:http\://en.wikipedia.org/wiki/Molluscum_contagiosum, url:http\://www.cdc.gov/ncidod/dvrd/molluscum/overview.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01348386 | Completed | Phase 2/Phase 3 | Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum | March 2010 | March 2012 |
| NCT03927703 | Completed | Phase 3 | A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC | June 13, 2019 | February 3, 2020 |
| NCT03927716 | Completed | Phase 3 | A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) | June 3, 2019 | January 29, 2020 |
| NCT04535531 | Completed | Phase 3 | A Phase 3 Molluscum Contagiosum Efficacy and Safety Study | September 1, 2020 | July 28, 2021 |
| NCT05634460 | Completed | Phase 1 | Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum | March 1, 2022 | August 31, 2022 |
| NCT05680181 | Completed | Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin | January 20, 2023 | January 26, 2024 | |
| NCT05897112 | Completed | Phase 1 | Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum | November 1, 2022 | April 30, 2023 |
| NCT02665260 | Completed | Phase 2 | Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum | July 2012 | January 2016 |
| NCT02902822 | Completed | N/A | Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo | October 2016 | May 2019 |
| NCT03017846 | Completed | Phase 2 | Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 | September 2016 | September 6, 2017 |
| NCT03077750 | Completed | Phase 2 | A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum | February 27, 2017 | April 27, 2018 |
| NCT03186378 | Completed | Phase 2 | Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. | June 8, 2017 | June 25, 2018 |
| NCT03377790 | Completed | Phase 3 | Cantharidin Application in Molluscum Patients-1 | March 21, 2018 | November 26, 2018 |
| NCT03377803 | Completed | Phase 3 | Cantharidin Application in Molluscum Patients | February 14, 2018 | September 26, 2018 |
| NCT03436615 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum | January 24, 2018 | November 3, 2018 |
| NCT02759900 | Recruiting | N/A | Using a Cold Atmospheric Plasma Device to Treat Skin Disorders | January 2016 | January 2025 |
| NCT05937672 | Recruiting | Phase 3 | Cold Atmospheric Plasma Device Extension Study | September 18, 2023 | August 1, 2024 |
| NCT02024581 | Terminated | Phase 2 | A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum | February 2016 | September 21, 2017 |
| NCT04476186 | Unknown status | N/A | The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children | June 15, 2020 | December 30, 2021 |
| NCT03336372 | Withdrawn | Early Phase 1 | Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients | December 20, 2017 | October 16, 2018 |
| NCT05536882 | Withdrawn | Phase 3 | MC RCT - BPO vs Adapalene | May 18, 2022 | October 9, 2023 |
- Disase is a (Disease Ontology)
- DOID:934
- Cross Reference ID (Disease Ontology)
- ICD10CM:B08.1
- Cross Reference ID (Disease Ontology)
- ICD9CM:078.0
- Cross Reference ID (Disease Ontology)
- MESH:D008976
- Cross Reference ID (Disease Ontology)
- NCI:C155872
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154360009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0026393
- ICD10 preferred id (Insert disease from ICD10)
- D0000513
- ICD10 class code (Insert disease from ICD10)
- B08.1
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008976